Hsp90 Inhibitors in Oncology: Ready for Prime Time?
Department of Oncology, Division of Medical Oncology, University of Calgary, and Tom Baker Cancer Centre, Calgary, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(5), 663-667; https://doi.org/10.3747/co.21.2163
Submission received: 3 July 2014
/
Revised: 5 August 2014
/
Accepted: 10 September 2014
/
Published: 1 October 2014
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
In the targeted oncology era, there has been a resurgence of interest in targeting members of the heat shock protein family, as evidenced by numerous ongoing trials in advanced malignancies (Table I).[...]
Share and Cite
MDPI and ACS Style
Parimi, S.; Tsang, R.Y. Hsp90 Inhibitors in Oncology: Ready for Prime Time? Curr. Oncol. 2014, 21, 663-667. https://doi.org/10.3747/co.21.2163
AMA Style
Parimi S, Tsang RY. Hsp90 Inhibitors in Oncology: Ready for Prime Time? Current Oncology. 2014; 21(5):663-667. https://doi.org/10.3747/co.21.2163
Chicago/Turabian StyleParimi, S., and R.Y. Tsang. 2014. "Hsp90 Inhibitors in Oncology: Ready for Prime Time?" Current Oncology 21, no. 5: 663-667. https://doi.org/10.3747/co.21.2163
